UNII EWQ57Q8I5X

LACTOSE MONOHYDRATE

Unique Ingredient Identifier EWQ57Q8I5X is listed as a ingredient substance
UniiEWQ57Q8I5X
Preferred Substance NameLACTOSE MONOHYDRATE
Rn64044-51-5
NcitC76719
Rxcui1305527
Pubchem104938
Molecular FormulaC12H22O11.H2O
InchikeyWSVLPVUVIUVCRA-KPKNDVKVSA-N
SmilesO.[H][[email protected]@]2(O[[email protected]@H]1[[email protected]@H](CO)O[[email protected]](O)[[email protected]](O)[[email protected]]1O)O[[email protected]](CO)[[email protected]](O)[[email protected]](O)[[email protected]]2O
Unii TypeINGREDIENT SUBSTANCE
RN64044-51-5
NCITC76719
RXCUI1305527
PUBCHEM104938
MFC12H22O11.H2O
INCHI KEYWSVLPVUVIUVCRA-KPKNDVKVSA-N
SMILESO.OC[[email protected]]1O[[email protected]@H](O[[email protected]@H]2[[email protected]@H](CO)O[[email protected]](O)[[email protected]](O)[[email protected]]2O)[[email protected]](O)[[email protected]@H](O)[[email protected]]1O

Alternate Names

Dosage Forms

UNII EWQ57Q8I5X LACTOSE MONOHYDRATE is commonly included in medications in the following forms.

RouteDosage FormPotency
BUCCALTABLET21.38 MG
IM - IVINJECTABLE2.5 %
IM - IVINJECTION2.5 %
IM - IVPOWDER2.75 %
IM - IVPOWDER, FOR INJECTION SOLUTION2.5 %
IM - IV - SCPOWDER, FOR INJECTION SOLUTION, LYOPHILIZED10.7 %
IM - SCINJECTION2.1 %
INHALATIONPOWDER24.95 MG
INHALATIONPOWDER2.5 %
INHALATIONPOWDER, FOR INHALATION2.2 MG/INH
INTRACAVITARYPOWDER, FOR INJECTION SOLUTION, LYOPHILIZED4.54 %
INTRAMUSCULARINJECTION5 %
INTRAMUSCULARPOWDER, FOR INJECTION SOLUTION10.7 %
INTRAMUSCULARPOWDER, FOR INJECTION SOLUTION, LYOPHILIZED5 %
INTRAVENOUSINJECTION4.5 %
INTRAVENOUSPOWDER, FOR INJECTION SOLUTION10.7 %
INTRAVENOUSPOWDER, FOR INJECTION SOLUTION, LYOPHILIZED69 %
IV - SCINJECTION4.9 %
IV(INFUSION)INJECTABLE4.5 %
IV(INFUSION)POWDER, FOR INJECTION SOLUTION20 %
IV(INFUSION)POWDER, FOR INJECTION SOLUTION1 %W/V
IV(INFUSION)POWDER, FOR INJECTION SOLUTION, LYOPHILIZED394.9 MG/Vial
IV(INFUSION)POWDER, FOR INJECTION SUSPENSION, LYOPHILIZED9.5 %W/V
ORALCAPSULE430.42 MG
ORALCAPSULE (IMMED./COMP. RELEASE)112 MG
ORALCAPSULE (IMMED./COMP. RELEASE), HARD GELATIN166.77 MG
ORALCAPSULE, COATED99.5 MG
ORALCAPSULE, COATED PELLETS33.09 MG
ORALCAPSULE, COATED, HARD GELATIN85 MG
ORALCAPSULE, COATED, SOFT GELATIN178.91 MG
ORALCAPSULE, DELAYED ACTION125.09 MG
ORALCAPSULE, DELAYED ACTION, COATED16 mg
ORALCAPSULE, DELAYED RELEASE76.4 MG
ORALCAPSULE, ENTERIC COATED PELLETS100 MG
ORALCAPSULE, EXTENDED RELEASE536.4 MG
ORALCAPSULE, HARD GELATIN199.5 MG
ORALCAPSULE, SUSTAINED ACTION147.6 MG
ORALCAPSULE, SUSTAINED ACTION, HARD GELATIN18.8 MG
ORALDISPERSIBLE TABLET543.6 MG
ORALGRANULE109.8 MG
ORALGRANULE, FOR ORAL SOLUTION1691.8 MG/SACHET
ORALGRANULE, FOR SUSPENSION NA
ORALPOWDER, FOR SUSPENSION NA
ORALTABLET708.9 MG
ORALTABLET333 MEQ
ORALTABLET (IMMED./COMP. RELEASE), COATED254 MG
ORALTABLET (IMMED./COMP. RELEASE), FILM COATED269.8 MG
ORALTABLET (IMMED./COMP. RELEASE), UNCOATED, CHEWABLE100 MG
ORALTABLET, CHEWABLE126.1 MG
ORALTABLET, COATED346.5 MG
ORALTABLET, CONTROLLED RELEASE152.75 MG
ORALTABLET, DELAYED ACTION385.55 MG
ORALTABLET, DELAYED ACTION, ENTERIC COATED157.95 MG
ORALTABLET, DELAYED RELEASE245 mg
ORALTABLET, ENTERIC COATED PARTICLES150 MG
ORALTABLET, EXTENDED RELEASE538 MG
ORALTABLET, FILM COATED587.44 MG
ORALTABLET, FILM COATED, EXTENDED RELEASE72.14 MG
ORALTABLET, FOR SUSPENSION4.9 MG
ORALTABLET, MULTILAYER, COATED22.7 MG
ORALTABLET, ORALLY DISINTEGRATING29.75 MG
ORALTABLET, REPEAT ACTION155.28 MG
ORALTABLET, SUSTAINED ACTION299.2 MG
ORALTABLET, SUSTAINED ACTION, FILM COATED260 MG
ORALTABLET, SUSTAINED RELEASE, FILM COATED81.9 MG
ORAL-20TABLET288.75 mg
RESPIRATORY (INHALATION)POWDER, FOR INHALATION2 %
SUBCUTANEOUSPOWDER, FOR INJECTION SOLUTION10.7 %
SUBLINGUALTABLET191.76 MG
SUBLINGUALTABLET (IMMED./COMP. RELEASE), UNCOATED, BUCCAL160.4 MG
VAGINALEMULSION, CREAM NA
VAGINALINSERT210 MG
VAGINALTABLET596 MG
VAGINALTABLET, FILM COATED17.9 MG

© 2020 FDA.report
This site is not affiliated with or endorsed by the FDA.